Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. The Venowave is a medical compression pump that is lightweight, compact, battery operated, designed to treat and alleviate the symptoms associated with poor circulation.


TSXV:THRM - Post by User

Comment by LosingHopeon Oct 07, 2021 4:54pm
118 Views
Post# 33983975

RE:RE:RE:RE:RE:You Realize that Merck has a pill that

RE:RE:RE:RE:RE:You Realize that Merck has a pill thatThe "pill" (Molnupiravir) you speak off is as useless as AcuVid is today.  Both have NOT received EUA from the FDA yet!  Will it be approved?  Maybe.  Will AcuVid?  We're all still waiting.  Time will tell.  Will Molnupiravir help control Covid in the future?  Sounds like it will help slow Covid by reducing hospitalizations and deaths by 50%NOT 100%.  When will you take Molnupiravir?  After you TEST positive for Covid (the sooner you start taking the pill the better, this "pill" will not help those already hospitalized or severely sick with Covid).  Will it make testing go away?  You have to TEST to determine if you have Covid, so not at all during the first year or two.  Plus, there is 7.9 Billion people and 195 countries on this planet.  Molnupiravir will not cleanse the planet of Covid over night.  Nothing will, not even vaccines!  It will definitely be very helpful yes, but NOT as helpful as vaccines.  It will take a combination of many "Proving" devices, vaccines and medicines to make Covid go away and many more years to BOOT.  

BTW, the only thing Ivermectin and "the pill" (Molnupiravir) have in common is:
  1. Merck help create and develop Ivermectin in the 80's as a parasite medication for animals 
  2. Merck is working in collaboration with Ridgeback (who holds the licence for Molnupiravir) to help develop and test Molnupiravir for FDA approval and distribution if successful. 
Molnupiravir was actually invented by DRIVE "Emory Institute for Drug Development at Emory University" and it has been in the news since at least March 2021.  See link below.  And people, do your DD before commenting on things and stay of Facebook and other social media pigs that spread falsehoods.

Cheers


https://news.emory.edu/stories/2021/03/coronavirus_DRIVE_molnupiravir/index.html

https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/
<< Previous
Bullboard Posts
Next >>